Pfizer Biohaven Acquisition Sparks Hope of More Biotech M&A
May 12, 2022 at 10:10 AM EDT
Earlier this week, Pfizer (NYSE:PFE) announced plans to acquire Biohaven Pharmaceutical (NASDAQ:BHVN) for $11.6 billion, sparking hopes of more biotechnology consolidation activity to come. Pfizer is paying a 33% premium for the maker of Nurtec ODT, a well-known migraine headache treatment. The...
